18272355. HIV Pseudovirus Particles and Method for Preparing the Same simplified abstract (BOE Technology Group Co., Ltd.)
Contents
- 1 HIV Pseudovirus Particles and Method for Preparing the Same
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 HIV Pseudovirus Particles and Method for Preparing the Same - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
HIV Pseudovirus Particles and Method for Preparing the Same
Organization Name
BOE Technology Group Co., Ltd.
Inventor(s)
HIV Pseudovirus Particles and Method for Preparing the Same - A simplified explanation of the abstract
This abstract first appeared for US patent application 18272355 titled 'HIV Pseudovirus Particles and Method for Preparing the Same
Simplified Explanation
The patent application describes a method for preparing HIV pseudovirus particles containing conserved sequences of genes from HIV-1 and a protein from phage MS2. The method involves designing target fragments and a gene sequence from phage MS2, synthesizing them, and inserting them into a vector to create a recombinant expression vector for the pseudovirus particles.
- Design target fragments and gene sequence from phage MS2
- Synthesize and insert them into a vector to create a recombinant expression vector
- Encapsulate pseudovirus particles with RNA conserved fragments from HIV-1
- Ensure high yield and stability of the pseudovirus particles
- Fast, convenient, efficient, and cost-effective method
Potential Applications
The technology could be used in research for studying HIV infection and developing antiviral drugs.
Problems Solved
This technology provides a method for producing stable and high-yield HIV pseudovirus particles for research purposes.
Benefits
The method offers a fast, convenient, and cost-effective way to prepare HIV pseudovirus particles with conserved sequences from HIV-1 and phage MS2.
Potential Commercial Applications
The technology could be valuable for pharmaceutical companies developing antiviral drugs targeting HIV.
Possible Prior Art
Prior methods for preparing HIV pseudovirus particles may not have utilized conserved sequences from both HIV-1 and phage MS2.
=== What are the specific conserved sequences used in the pseudovirus particles? The abstract does not specify the exact conserved sequences used in the pseudovirus particles.
=== How do the pseudovirus particles compare to natural HIV particles in terms of infectivity? The abstract does not mention how the infectivity of the pseudovirus particles compares to natural HIV particles.
Original Abstract Submitted
HIV pseudovirus particles and method for preparing the same. The pseudovirus particles contain conserved sequences of gag, pol and LTR regions on genes from HIV-1 and a protein from phage MS2. The method comprises the following steps: designing and selecting target fragments and a sequence of gene from phage MS2; direct synthesizing both of them respectively; inserting the sequence of gene from phage MS2 into pETDuet-1 vector to obtain pETDuet-MS2 vector; inserting the target fragments into pETDuet-MS2 vector to obtain pETDuet-MS2-HIV recombinant expression vector. The sequence of gene from phage MS2 and target fragments respectively are located between any restriction sites behind the 3′ends of two T7 promoters of pseudovirus particles. The pseudovirus particles are encapsulated with a plurality of RNA conserved fragments from HIV-1 simultaneously, and have high yield and good stability. The method is fast, convenient, efficient and cost-effective.
